Charlson-Deyo Comorbidity Index as a Novel Predictor for Recurrence in Non-Muscle-Invasive Bladder Cancer
Lukas Scheipner1, Hanna Zurl1, Julia V Altziebler1
1Department of Urology, Medical University of Graz, 8010 Graz, Austria.
Cancers
|December 23, 2023
Summary
Higher comorbidity burden, measured by the Charlson-Deyo Comorbidity Index (CCI), is associated with an increased risk of non-muscle-invasive bladder cancer (NMIBC) recurrence. Patients with more comorbidities require closer adherence to follow-up protocols.
Area of Science:
- Urology
- Oncology
- Public Health
Background:
- Non-muscle-invasive bladder cancer (NMIBC) recurrence is a significant clinical challenge.
- Patient comorbidities can influence cancer outcomes and treatment adherence.
- The Charlson-Deyo Comorbidity Index (CCI) is a widely used measure of health status.
Purpose of the Study:
- To investigate the association between the Charlson-Deyo Comorbidity Index (CCI) and the risk of recurrence in patients with non-muscle-invasive bladder cancer (NMIBC).
Main Methods:
- Retrospective analysis of 1072 NMIBC patients treated between 2010 and 2018.
- Utilized Kaplan-Meier estimates and Cox regression models to assess recurrence risk based on CCI.
- Comorbidity burden categorized as low (CCI ≤ 4) versus high (CCI > 4) and as a continuous variable.
Main Results:
- Patients with high comorbidity burden (CCI > 4) showed a significantly higher risk of NMIBC recurrence.
- Multivariable analysis confirmed that high CCI independently predicted increased recurrence risk (HR 1.42, p=0.018).
- Each one-unit increase in CCI was associated with a 5% increased hazard of recurrence (HR 1.05, p=0.04).
Conclusions:
- Comorbidities are prevalent in NMIBC patients and are linked to poorer outcomes.
- Higher CCI scores are associated with an elevated risk of bladder cancer recurrence.
- NMIBC patients with high comorbidity burden warrant intensified adherence to surveillance and follow-up guidelines.
More Related Videos
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
01:08Prevalence and Incidence
In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health condition at a...
Prevalence indicates the proportion of individuals in a population who have a specific disease or health condition at a...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
01:26Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Renal calculi, commonly termed kidney stones, are crystalline solid masses that form in the kidneys but can occur at any point within the urinary system, encompassing the kidneys, ureters, bladder, and urethra.The pathophysiology of renal stones involves several key factors: supersaturation of the urine with stone-forming constituents, changes in urine pH, a decrease in urine volume, and the presence of substances that promote or inhibit stone formation.Supersaturation of Urine: This is the...